Clinical Trials

Phase 2 Active not recruiting

Lymphoma, Lymphoma, Non-Hodgkin, Hematologic Neoplasms

NCT03580928 2026-02-13

AVO

72 enrolled 12 charts

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02427451 2026-01-27

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

87 enrolled 30 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04150029 2026-01-13

STIMULUS-AML1

90 enrolled 26 charts

Leukemia, Myeloid, Acute

NCT05799079 2026-01-09

Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

1 enrolled 8 charts

Leukemia, Myeloid, Acute

NCT05184842 2026-01-05

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

Phase 2 Recruiting

91 enrolled 26 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05464836 2025-11-26

Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL

2 enrolled 10 charts

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02242942 2025-11-06

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

445 enrolled 22 charts 1 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04874194 2025-11-03

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

24 enrolled 15 charts

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04266795 2025-10-21

PEVENAZA

164 enrolled 12 charts

Leukemia, Myeloid, Acute

NCT03069352 2025-09-30

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

211 enrolled 30 charts 2 FDA

Leukemia, Leukemia, Myeloid, Acute

NCT05168202 2025-09-25

A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Phase 1 Terminated

56 enrolled 24 charts

Phase 1/2 Active not recruiting

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05192889 2025-09-22

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

35 enrolled 12 charts

Phase 3 Active not recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04102020 2025-08-20

VIALE-M

112 enrolled 13 charts

Phase 3 Active not recruiting

Leukemia, Myeloid, Acute

NCT02993523 2025-08-19

Viale-a

443 enrolled 14 charts 2 FDA

Leukemia, Myeloid, Acute

NCT02397720 2025-06-08

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

150 enrolled 17 charts

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04752163 2025-05-23

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

LymphoidMyeloidOther hematologic neoplasm

17 enrolled 15 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03576547 2025-05-08

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

LymphoidMyeloidOther hematologic neoplasm

9 enrolled 11 charts

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04070768 2025-05-04

Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

Phase 1 Completed

18 enrolled 15 charts

Recurrence, Leukemia, Myeloid, Acute

NCT04487106 2025-04-22

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

21 enrolled 14 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03492125 2025-04-10

A Study Of The Selective PKC-β Inhibitor MS- 553

60 enrolled 20 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05079230 2025-04-04

ENHANCE-3

Phase 3 Terminated

378 enrolled 29 charts

Leukemia, Myeloid, Acute

NCT04277442 2025-03-25

Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia

Phase 1 Completed

1 enrolled 8 charts

Leukemia, Myeloid, Acute

NCT04419389 2025-03-17

R/R

1 enrolled 4 charts

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT04905407 2025-02-24

Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

66 enrolled 21 charts

Leukemia, Myeloid, Acute

NCT04778397 2025-02-05

ENHANCE-2

Phase 3 Terminated

258 enrolled 25 charts

Leukemia, Myeloid, Acute

NCT02910583 2024-12-20

Captivate

323 enrolled 33 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04029688 2024-12-20

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

CNSLymphoidOther hematologic neoplasm

38 enrolled 34 charts

Neuroblastoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03735875 2024-09-19

Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia

8 enrolled 13 charts

Leukemia, Myeloid, Acute

NCT04659044 2024-09-19

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

3 enrolled 11 charts

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

120 enrolled 14 charts

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03176277 2024-07-15

A Study of ONO-7475 in Patients With Acute Leukemias

42 enrolled 47 charts

Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03801525 2024-04-19

ULTRA-V

Phase 2/3 Terminated

277 enrolled 19 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02005471 2023-10-17

MURANO

389 enrolled 35 charts 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03390296 2023-09-05

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Completed

50 enrolled 13 charts

Leukemia, Myeloid, Acute

NCT04016805 2023-07-24

Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

41 enrolled 4 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03634228 2023-06-15

Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia

16 enrolled 13 charts

Leukemia, Myeloid, Acute

NCT04146038 2023-05-24

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

5 enrolled 9 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03941964 2023-03-20

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

60 enrolled 12 charts

Neoplasms, Leukemia, Myeloid, Acute

NCT02980731 2023-02-22

VENICE II

210 enrolled 36 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02287233 2022-08-29

A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

Phase 1/2 Completed

94 enrolled 37 charts

Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT02639910 2021-12-20

COSMOS

24 enrolled 13 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01889186 2021-12-16

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

158 enrolled 21 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03045328 2021-09-29

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

22 enrolled 14 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01994837 2018-06-06

A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

32 enrolled 14 charts